We are live on ! Find out more
BLRX

BioLineRX
BLRX

31 hedge funds and large institutions have $16.3M invested in BioLineRX in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $15.7M → $16.3M (+$524K)

0.01% less ownership

Funds ownership: 0.05% → 0.04% (-0.01%)

9% less funds holding

Funds holding: 34 → 31 (-3)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
+$1.32M
2
DG
Delek Group
Israel
+$105K
3
SM
Sabby Management
Florida
+$18.1K
4
CCB
Cutter & Co Brokerage
Missouri
+$11.1K
5
VF
Virtu Financial
New York
+$6.12K

Top Sellers

Rank Fund Capital Flow
1
FI
Fosun International
China
-$304K
2
MC
Menta Capital
California
-$33K
3
Renaissance Technologies
Renaissance Technologies
New York
-$27K
4
Deutsche Bank
Deutsche Bank
Germany
-$26K
5
TSS
Two Sigma Securities
New York
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$11.2M – – –
SM
2
Senvest Management
New York
$3.24M +$1.32M +4,542 +57%
O
3
OrbiMed
New York
$447K – – –
Morgan Stanley
4
Morgan Stanley
New York
$406K -$19.2K -66 -4%
FI
5
Fosun International
China
$313K -$304K -1,045 -46%
EMG
6
ETF Managers Group
New Jersey
$157K -$5.82K -20 -3%
OM
7
Opaleye Management
Massachusetts
$108K – – –
DG
8
Delek Group
Israel
$92K +$105K +359 New
SAM
9
Sectoral Asset Management
Quebec, Canada
$77K -$9.61K -33 -10%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$33K -$22.7K -78 -38%
VanEck Associates
11
VanEck Associates
New York
$25K +$582 +2 +2%
CCB
12
Cutter & Co Brokerage
Missouri
$25K +$11.1K +38 +67%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$24K – – –
NFG
14
Next Financial Group
Texas
$17K – – –
Wells Fargo
15
Wells Fargo
California
$17K – – –
NFH
16
NEXT Financial Holdings
Texas
$17K +$19.5K +67 New
SM
17
Sabby Management
Florida
$16K +$18.1K +62 New
Citadel Advisors
18
Citadel Advisors
Florida
$14K -$11.9K -41 -42%
MCC
19
Malaga Cove Capital
California
$10K – – –
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
$9K – – –
DBRC
21
D.B. Root & Company
Pennsylvania
$9K – – –
LPL Financial
22
LPL Financial
California
$6K – – –
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$5K -$2.91K -10 -32%
UBS Group
24
UBS Group
Switzerland
$5K +$874 +3 +18%
VF
25
Virtu Financial
New York
$5K +$6.12K +21 New
1
2

BLRX Hedge Fund Activity: Q1 2019 in Review

31 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2019, worth a combined $16.3M — up 3.3% from $15.7M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BLRX and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Senvest Management, adding an estimated $1.32M. The largest seller was Fosun International, cutting an estimated $304K.

  • 31 institutional investors held BioLineRX (BLRX) as of Q1 2019, down from 34 in Q4 2018.
  • Funds reported $16.3M of BioLineRX stock for Q1 2019, up 3.3% quarter-over-quarter.
  • 5 funds opened new BioLineRX positions in Q1 2019 and 7 closed out, a net change of -2 holders.
  • The largest BioLineRX buyer in Q1 2019 was Senvest Management, an estimated $1.32M added.
  • The largest BioLineRX seller in Q1 2019 was Fosun International, an estimated $304K sold.

Based on aggregated 13F filings for Q1 2019.